RedHill invited to give prestigious oral presentation of important data detailing high eradication rates across body mass index (BMI) groups with Talicia, the U.S.s leading brand for Helicobacter pylori. Opaganib for COVID-19 suggested host-directed mechanism of action described in Drug Design, Development and Therapy journal.
💼 Business Developments:
✅ Partnership/Collaboration
✅ Acquisition Activity
❌ Licensing Agreement: Not reported
✅ Regulatory Milestone
❌ Leadership Updates: Not reported
📞 Contact Information:
Media Contact: s: U.S. / UK: Amber Fennell, Consilium +44 (0) 7739 658 783 fennell@consilium-co
🌍 RedHill Biopharma (RDHL) - Form 6-K Filing
Filing Date: 2022-07-12
Accepted: 2022-07-12 08:03:27
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: